Innovations and challenges in renal cancer: Consensus statement from the first international conference Journal Article
| Authors: | Atkins, M. B.; Avigan, D. E.; Bukowski, R. M.; Childs, R. W.; Dutcher, J. P.; Eisen, T. G.; Figlin, R. A.; Finke, J. H.; Flanigan, R. C.; George, D. J.; Goldberg, S. N.; Gordon, M. S.; Iliopoulos, O.; Kaelin, W. G. Jr; Linehan, W. M.; Lipton, A.; Motzer, R. J.; Novick, A. C.; Stadler, W. M.; Teh, B. T.; Yang, J. C.; King, L. |
| Article Title: | Innovations and challenges in renal cancer: Consensus statement from the first international conference |
| Abstract: | Renal cell carcinoma is a serious medical problem in the United States, with nearly 35,000 new cases and >12,000 cancer-related deaths reported in 2003 (21). A number exciting advances in understanding the genetics, biology, and prognostic and predictive factors for renal cell carcinoma, as well as better local therapies, are improving the outlook for patients with advanced renal cell carcinoma. Although combinations of various treatment approaches might produce synergistic antitumor activity, we lack the mechanisms to rapidly and efficiently identify potentially effective combinations. Good surrogates of biological effect are needed to efficiently study strategies for combining various approaches. Nonetheless, for the first time in many years, investigators are primed to make significant advances in the treatment of renal cell carcinoma. |
| Keywords: | unclassified drug; thalidomide; clinical trial; sorafenib; bevacizumab; interferon; hypertension; patient selection; conference paper; cancer staging; protein function; treatment indication; disease association; interleukin 2; cancer immunotherapy; dendritic cell; protein binding; prediction; kidney carcinoma; kidney neoplasms; nephrectomy; temsirolimus; cytokine; immunotherapy; cancer vaccine; medical research; patient coding; medical specialist; allogeneic hematopoietic stem cell transplantation; consensus development; isotretinoin; birt hogg dube syndrome; kidney cancer; von hippel lindau disease; mammalian target of rapamycin inhibitor; hypoxia inducible factor 1alpha; everolimus; proteinuria; adverse drug reaction; von hippel lindau protein; protein inhibitor; fumarate hydratase; inheritance; raf protein inhibitor; ap 23573; hypoxia inducible factor 2alpha; humans; prognosis; human; priority journal |
| Journal Title: | Clinical Cancer Research |
| Volume: | 10 |
| Issue: | 18 Part 2 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2004-09-15 |
| Start Page: | 6277s |
| End Page: | 6281s |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-040720 |
| PROVIDER: | scopus |
| PUBMED: | 15448017 |
| DOI/URL: | |
| Notes: | Clin. Cancer Res. -- Cited By (since 1996):24 -- Export Date: 16 June 2014 -- CODEN: CCREF -- Source: Scopus |
